Trials / Completed
CompletedNCT01182142
Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 51 (estimated)
- Sponsor
- Kidney Cancer Research Bureau · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine | 1,250 mg/m2 orally twice a day, days 1-14 |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-09-01
- Completion
- 2010-08-01
- First posted
- 2010-08-16
- Last updated
- 2010-08-24
Locations
1 site across 1 country: Russia
Source: ClinicalTrials.gov record NCT01182142. Inclusion in this directory is not an endorsement.